Company profile: Aligos Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule and oligonucleotide platforms and a pipeline of drug candidates for MASH and viral diseases, including COVID-19 protease inhibitors (partly funded by NIH and NIAID), a capsid assembly modulator (ALG-000184) for chronic hepatitis B, STOPSTM to reduce HBV S-antigen, and next-generation antisense oligonucleotides (e.g., ALG-020572).
Products and services
- Antisense Oligonucleotide (ASO): Next-generation antisense oligonucleotides for hepatitis B, including ALG-020572, demonstrate in vivo efficacy and reduced hepatotoxicity
- Capsid Assembly Modulator (CAM): ALG-000184 is a mechanism-specific drug candidate targeting capsid assembly in chronic hepatitis B
- Pipeline of Drug Candidates: A clinically validated portfolio targeting multiple mechanisms of action for MASH and viral diseases.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aligos Therapeutics
Inozyme Pharma
HQ: United States
Website
- Description: Provider of therapies for rare diseases of calcification affecting soft tissues and bone, including a clinical-stage enzyme therapy (INZ-701) for pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Conducts clinical trials, offers a genetic testing process for ENPP1 Deficiency, and provides patient and family support and community resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inozyme Pharma company profile →
Intercept Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule drugs and therapeutics for chronic fibrotic and metabolic diseases, including INT-747, an FXR modulating agent for chronic autoimmune liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intercept Pharmaceuticals company profile →
Baronova
HQ: United States
Website
- Description: Provider of clinical-stage medical devices under development to induce weight loss through non-surgical, non-pharmacologic approaches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baronova company profile →
MetaVia Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage multimodal disease-modifying therapies, including DA-1241, an oral GPR119 agonist in Phase 2a for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and DA-1726, a once-weekly dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity, with a Phase 1 clinical trial expected to begin in 2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaVia Therapeutics company profile →
Crinetics
HQ: United States
Website
- Description: Provider of clinical-stage pharmaceutical research and development focused on therapies for people with rare endocrine diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crinetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aligos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aligos Therapeutics
2.2 - Growth funds investing in similar companies to Aligos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aligos Therapeutics
4.2 - Public trading comparable groups for Aligos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →